Updated shot is expected to better target variants that are circulating now and help prevent hospitalization and death from the virus
FDA Grants Full Approval to Paxlovid to Treat COVID-19
Paxlovid has been taken by seniors and others at high risk for severe COVID-19 under an emergency use approval
FDA Approves First Home Test to Detect Both Flu and COVID-19
Test will be sold without a prescription and can be used by anyone 14 years and older or by an adult on children ages 2 years and older
FDA Gives Moderna COVID-19 Vaccine Full Approval
Vaccine, which has been available for the age group under emergency use authorization, will be marketed as Spikevax
Most COVID-19-Related EUAs Not Supported by High-Quality Evidence
Most EUAs were for diagnostic products; most supported by comparisons with previously authorized assays, analytical in vitro studies
FDA Gives OK to Merck Antiviral At-Home COVID-19 Pill
Molnupiravir cut the risk for hospitalization and death in high-risk patients by 30 percent
FDA Approves Pfizer Pill as First At-Home COVID-19 Treatment
Recent trial showed Paxlovid cut the odds for hospitalization and death by nearly 90 percent in high-risk people
FDA Approves Drug to Help Immunocompromised Fend Off COVID-19
One dose of Evusheld is administered as two separate, consecutive injections and may be effective for six months
REGEN-COV Authorized for Postexposure Prophylaxis in High-Risk Individuals
Emergency use authorization indicated for those who have been exposed to SARS-CoV-2 and have an immunocompromising condition
FDA Approves Third COVID-19 Antibody Treatment for Emergency Use
Study found that patients who received sotrovimab showed an 85 percent reduction in their risk for hospitalization or death versus placebo
- Page 1 of 2
- 1
- 2